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Drug Resistance in Oncology
Edited by B. Teicher, New York: Marcel Dekker, 1993,
672 pp. $195.00.
This large book contains 26 generally informative and well-
written chapters addressing various aspects of cell or tumour
biology relating to therapeutic responsiveness. The list of
contributing authors is distinguished and includes many of
the leading experts in their fields.
In her preface, the editor explains her philosophy of re-
garding therapeutic resistance as a very broad issue involv-
ing, amongst other things, cellular biochemistry, tumour
physiology and host metabolism. She is clearly correct in
doing so, but I still cannot see why the book was given the
title which it carries. 'Drug resistance' may be a current
'buzzword(s)', but many of the chapters relate equally to
radiation responsiveness as to drug responsiveness, and
several have only the most remote connection with either.
Something along the lines of 'The Biology of Therapeutic
Response in Oncology' would have given a much more
accurate idea of the content.
In accord with the philosophy, the book begins with a
section entitled 'Physiological Resistance in Solid Tumours'.
This consists of seven chapters on topics such as the role of
blood flow, pH and oxygenation in tumour metabolism. The
second section, 'Biological Resistance', goes on to include
topics such as tumour cell heterogeneity, cell population
interactions and characterisation of the metastatic phenotype
within a total of six chapters. It is only upon reaching the
third section, 'Biochemical Resistance', that many readers
will, I suspect, find what they expect from the title of the
book. Five chapters discuss the fairly standard aspects of
drug resistance including GSH, P-glycoprotein and topoiso-
merases. Less predictable are chapters on 'Tumour cell drug
metabolism and drug resistance' (by D.E. Chapman and G.
Powis) and 'Oxazaphosphorine-specific acquired cellular
resistance' (by N. Sladek), which I found interesting and
valuable. (By the way, how many people can name at least
one oxazaphosphorine?) Section four, 'The Role of Hor-
mones, Growth Factors and Oncogenes', has five chapters,
including a particularly comprehensive and well-referenced
chapter on 'Antiestrogen resistance in breast cancer' (by R.
Clarke and M.E. Lippman). The final section, 'Clinical Re-
sistance', consists of only one, relatively short, chapter by
L.A. Ayash, T.S. Heman and E. Frei III. It seems to me
inappropriate that a very large book (672 pages) entitled
'Drug Resistance in Oncology' should contain only 14 pages
of text devoted specifically to consideration of clinical resist-
ance. A much more comprehensive account of topics such as
the role of non-cross-resistant therapies, high-dose therapy,
bone marrow transplantation, late dose intensification and
prolonged maintenance therapy would surely have been
valuable.
I am always curious as to what instructions were given to
authors regarding the detailed preparation of their chapters.
One gains the impression that no instructions were given as
to the reference system to be used. Most of the chapters use
standard Vancouver system. However, that by Chapman and
Powis uses the Harvard system, whilst that by Futscher and
Dalton has a reference list omitting the titles of the papers.
Not good enough! The efforts made by the authors in illust-
rating their chapters with appropriate figures and tables are
also extremely variable. The median number of figures plus
tables per chapter is 4 (range 0-21). I find it hard to believe
that, for example, the long chapter by Chapman and Powis
(30 pages of text, 260 references) is optimally presented with-
out a single figure or table.
It is always critical in assessing a book such as this to
consider how up to date the material is. The book was
published in February 1993 and, fairly predictably, contains
very few 1992 references. There are reasonable numbers of
1991 references, but also a smattering of 1991 (in press). I
also spotted a reference (in the Chapter by Kerbel and
MacDougall) to a paper, with Dr Kerbel as an author, given
as Int. J. Cancer 1990 (submitted), which is odd to say the
least. In late 1993, therefore, the potential reader has, as
usual, to ask the question whether, in such rapidly moving
fields, the material is sufficiently timely to be regarded as
definitive.
The volume contains an enormous amount of valuable
material together with some which is less valuable. It is also
enormously expensive. I think that it would have been a
better book had it attempted to be rather less ambitious and
somewhat more focused. It would certainly benefit from a
more appropriate title. I believe that it will be bought by
some major institutional libraries but I do not think that
many individuals will wish to pay the price.
P.R. Twentyman
Oxford Textbook of Pafliative Medicine
Edited by D. Doyle, G.W.C. Hanks & N. MacDonald,
Oxford: Oxford University Press, 1993, 845 pp.
The casual reader may well be daunted by the rather austere
covers of this weighty tome and by the number of
authors-103 in all. However, once Dame Cicely Saunders'
foreword has been digested, their appetite will be whetted for
the rest of the book. The publication of the Oxford Textbook
of Palliative Medicine is both timely and topical; it brings
together a wealth of experience from a wide range of discip-
lines and specialties and provides the most cohesive and
comprehensive guide to this evolving field yet available.
In their preface the editors do not address a specific target
audience. Cancer nurses, physicians and surgeons, candidates
preparing for professional examinations and members of
multidisciplinary palliative care teams will all undoubtedly
find it a useful resource. In addition, however, this book
contains 'something for everyone', including health
economists and purchasers of health care. Although the main
emphasis, particularly in the chapters on symptom control, is
on the palliation of symptoms in patients with malignant
disease, wider general principles are expounded which are
relevant to patients with symptoms irrespective of their
pathology. Specific chapters on paediatric palliative care and
palliative aspects of adult acquired immune deficiency syn-
dromes are especially welcome.
Slightly less than half the book is devoted to clear and
easily readable reviews of symptom management. These
chapters are based on both research and extensive clinical
experience, and most authors extend their discussion beyond
therapeutic strategies to a consideration of other aspects of
their subject, including its pathophysiology. Justifiably long
and detailed dissertations on the treatment of major symp-
toms such as pain and dyspnoea sit well alongside short but
pertinent sections on the management of problems as diverse
as sweating, lymphoedema and hiccoughs. Unfortunately,
areas where the interface between basic science and clinical
practice is particularly fruitful and where research is currently
active, such as the management of neuropathic pain, are
almost by definition already out of date. This is unavoidable,
and those chapters which suffer from this drawback are,
nonetheless, some of the most interesting.
The reader who still regards palliative care as purely 'ter-
minal care' will be surprised that only 14 of the 817 pages are
specifically devoted to the management of the 'terminal
phase' of illness. The basic premise that palliative care is794 BOOK REVIEWS
active treatment rather than a negative lack of treatment or,
as Professor Stjernsward puts it, 'a waste-paper basket alter-
native' runs throughout the text and unifies the whole. The
holistic and interdisciplinary nature of palliative care is
emphasised by comprehensive and well-written chapters on
ethical, cultural and spiritual issues and bereavement. The
section on rehabilitation is noteworthy in that it covers topics
as diverse as stoma management and music therapy as well
as incontrovertibly demonstrating that rehabilitation is an
intrinsic part of palliative medicine.
The importance of research in palliative care is a recurring
theme throughout the book, and a specific section is devoted
to this topic. Studies in this field are, however, relatively
sparse, and the reasons for this are acknowledged and duly
addressed. In particular, Calman and Hanks refer to the
widespread view that 'scientifically rigorous clinical research
is incompatible with the basic tenets of palliative care', and
they put forward cogent arguments to refute this. This sec-
tion of the book is extremely wide-ranging, and discussion is
not limited to research into pharmacological and non-
pharmacological symptom management as nursing, psycho-
logical and social issues are also well covered. The fact that
palliative care crosses the traditional barriers of discipline
and specialty is highlighted in the section on education and
training. The authors stress that all the members of any
hospital-based or domiciliary team caring for patients with
cancer, be they doctors, nurses, social workers, physio-
therapists or clergy, need at least a working knowledge of the
philosophy of palliative care and suggest that this subject
should become an integral part of the curriculum of all
student health care professionals.
Although multiauthorship can bring problems through
inevitable variability of both style and approach, these are
not very apparent and there is a uniformly high standard of
presentation throughout the book. Despite a degree of over-
lap between chapters there is surprisingly little repetition. The
textbook is well indexed and all of the chapters are more
than adequately referenced. In parts, the text is rather dry
and it is tempting to speculate that it could be lightened by
more case histories and illustrations.
The book concludes with a thought-provoking dissertation
on the global perpsective of palliative medicine. Each year
fifty million people die worldwide. At least 10% die of
malignant disease, and it is likely that this proportion, in
addition to the numbers dying from AIDS-related diseases,
will continue to increase. Given that even in resource-rich,
developed nations there is inadequate application of the
available knowledge on palliative care, it is perhaps not
surprising that globally this field of medicine is badly
neglected. To rectify this situation changes are necessary not
only in medical practice but also in political, socioeconomic,
social and ethical arenas. The World Health Organization
has designated palliative care a priority in its Global Cancer
Control Programme, and encouraging progress is already
being achieved.
The Oxford Textbook ofPalliative Medicine is a book both
to dip in to, at leisure and when faced with an urgent clinical
problem to solve, and to read systematically to gain a full
insight into this field. Whilst its publication undoubtedly
represents a coming of age of palliative medicine as a
specialty in its own right, it is equally obvious that this new
specialty must continue to evolve.
Carol L. Davis
Chemoradiation. An Integrated Approach to Cancer Treatment
Edited by M.J. John, M.S. Flam. S.S. Legha & T.L. Phillips,
Philadelphia: Lea & Febiger, 1993. 688 pp. £75.00.
This book sets out to put forward the rationale for and
history to date of integrating chemotherapy and radiation in
the management of cancer. The book is divided into five
sections, with a brief introduction, the biological principles
underlining combined modality therapy, a clinical section
covering 17 disease sites, a section on toxicity and an appen-
dix summarising current clinical trials addressing the issue.
The second section includes some basic information about
the mechanisms and action of both radiation and cytotoxic
drugs, but most attention is focused on their use as sole
modalities with little information about possible interactions.
The clinical chapters are comprehensive and give an excellent
overview of combined modality therapy in the individual
disease sites. The section on toxicity tends to reproduce some
of the information included in the clinical chapters. Overall,
this book may be useful as a reference source in a depart-
mental library but it is unlikely to be of everyday relevance
to the majority of oncology clinicians.
G.M. Duchesne
New Approaches in Cancer Pharmacology: Drug Design and
Development
Edited by P. Workman, Berlin: Springer-Verlag, 1992,
103 pp.
This European School of Oncology Monograph recounts the
deliberations of a Task Force set up to examine current
progress and to anticipate future trends in cancer drug dis-
covery and pharmacology. The underlying theme is the need
for more effective drugs and the exciting opportunities
offered by the present understanding of the discrete mole-
cular abberations ofmalignant cells which provide targets for
selective attack. The contributors are all acknowledged
experts in their fields and this short monograph is well
written, authoritative and readable.
The review on sequence- and gene-specific drugs by D'In-
calci, Broggini and Hartley concentrates on alkylating agents
and their reactions with DNA as the major biochemical
events underpinning their cytotoxicities. It has been known
for some time that DNA damage is attributable to single-
and double-strand breaks, inter- and intra-strand cross-links
and possibly to DNA-protein cross-links. The site most
frequently alkylated is guanine N7, with lesser reaction occur-
ring at guanine 06 and adenine N3. The authors review
methodology which now enables an understanding of how
DNA base sequences influence the sites of alkylation of
various clinically used alkylating agents. It is now clear that
many common bifunctional alkylating agents react preferen-
tially with guanine N7 in contiguous runs of guanines in the
major groove of DNA. The authors emphasise that these
studies are carried out with parent drug and purified DNA
and take no account of cellular metabolism. Minor groove
binders include mitomycin C and CC-1065.
Claude Helene discussed antisense and antigene oligo-
nucleotides and synthetic ribozymes. The major requirements
of antisense oligos are emphasised: nuclease stability; preser-
vation of RNAse H activity; good cell penetration. The
advantages and shortcomings of the various linker chemis-
tries and the properties of chimaeric molecules comprising
conventional phosphodiester linkers in association with
methyl phosphonate, phosphorothioate or phosphoramidate
units is reviewed. Other chemical manoeuvres, including
coupling of oligos to hydrophobic moieties to enhance trans-
port and attachment of alkylating residues, both to achieve
nuclease stability and to increase potency, are mentioned
also. A consistent theme is the high selectivity that can be
achieved with antisense oligonucleotides in their effects, for
example on parasitically or virally infected cells, as well as on
tumour cells carrying a single point mutation in the Ha-ras
oncogene, amplified c-myc or in CML cells, where the
bcr-abl translocation can be targeted. Oligonucleotide-
directed triple helix formation, where Hoogstein hydrogen
bonding permits the association of a third oligo strand with
the nuclear DNA, is described as an 'anti-gene' strategy. The
triple helix can be effectively stabilised by the attachment of a
'docking' intercalator molecule. It is envisaged that this
approach will interfere with the function of transcription
factors and restriction enzymes, thus disturbing differ-
entiation and cell division. The author concludes that the